NEUROFIBROMA, PLEXIFORM
Clinical trials for NEUROFIBROMA, PLEXIFORM explained in plain language.
Never miss a new study
Get alerted when new NEUROFIBROMA, PLEXIFORM trials appear
Sign up with your email to follow new studies for NEUROFIBROMA, PLEXIFORM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Tracking a new Drug's Real-World impact on Kids' debilitating tumors
Disease control OngoingThis study aims to understand how well the drug selumetinib works and how safe it is for children in China with inoperable, painful tumors caused by a genetic condition called Neurofibromatosis Type 1 (NF1). It will follow about 80-100 children aged 3-16 years for up to 2 years a…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 04, 2026 00:06 UTC
-
First chinese trial tests drug for rare genetic nerve tumors
Disease control OngoingThis early-phase study is testing the safety and effects of the drug selumetinib in Chinese children and adults with Neurofibromatosis Type 1 (NF1) who have inoperable nerve tumors called plexiform neurofibromas. About 32 participants will take the oral medication twice daily unt…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
New hope for kids with untreatable tumors
Disease control OngoingThis study tested an oral drug called selumetinib in children and young adults with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas—nerve tumors that cannot be safely removed by surgery. The goal was to see if the drug could shrink these tumors or stop them from g…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC